多替阿巴拉米片治疗艾滋病疗效怎样？

The English name is Triumeq, which consists of three drugs: dolutegravir 50mg (dolutegravir) + abacavir 0.6g (abacavir) + lamivudine 0.3g (lamivudine). It is used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. It takes one tablet once a day. It has the characteristics of high efficiency, good tolerance, high resistance barrier and few drug interactions. Dolutegravir tablets are currently the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. Today we are going to find out how effective Dota Abalami Tablets is in treating AIDS? 

In a phase I/II 48-week multicenter, open-label study (P1093/ING112578), the pharmacokinetic parameters, efficacy, tolerability, and safety of dolutegravir were evaluated in HIV-I-infected infants, children, and adolescents receiving the combination regimen. At week 24, 16 of 23 adolescents (aged 12 to 17 years) who received once-daily dolutegravir (35mgn=4; 50mgn=19) plus OBR achieved viral loads <50 copies/mL. In 20 of 23 children and adolescents (87%), the reduction in HIV-1 RNA from baseline at week 24 was greater than 1 log10 copies/mL or HIV-1 RNA <400 copies/mL. Four subjects experienced virological failure, but none had INI resistance at the time of virological failure.

Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Comparing it with patients who failed the first-line regimen of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), doteabalamid (Inbec) has significantly fewer drug-resistant mutations than the other two drugs, making it less likely to develop drug resistance.  

Dote abalamib tablets are based on DTG, an integrase inhibitor, as the core drug. In the real world, antiviral treatment-naïve patients treated with DTG are better than RAL (Ascent), DRV/r (darunavir), EFV (efavirenz). ) and ATV/r (atazanavir) have a lower proportion of central nervous system-related (CNS) adverse events. Therefore, the drug safety of dolutea palamid tablets, which is based on DTG integrase inhibitors, has proven to be controllable.  

The above is the content of the efficacy, I hope it can help you!